ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Serenity Patients to Benefit Immediately from FDA-Cleared Accelerated Deep TMS™ Protocol

Patients nationwide can access faster, convenient TMS treatment at Serenity clinics.

Serenity Mental Health Centers, a leader in innovative psychiatric care and one of the fastest-growing mental health providers in the nation, today highlights the FDA’s recent clearance of BrainsWay’s accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) protocol for Major Depressive Disorder (MDD), including patients with comorbid anxiety. Because Serenity already uses BrainsWay machines in its clinics, patients can now benefit immediately from this faster, convenient, and non-invasive treatment option.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251001671120/en/

Patients nationwide can access faster, convenient TMS treatment at Serenity clinics.

Patients nationwide can access faster, convenient TMS treatment at Serenity clinics.

“Serenity is the largest provider of Deep TMS in the country and is one of the only practices certified to conduct its own TMS training,” said Tricia Pease, COO and co-founder of Serenity Mental Health Centers. “These distinctions allow Serenity technicians to receive the highest level of instruction, therefore consistently delivering a high quality of care.”

The accelerated protocol reduces the acute phase from four weeks to just six treatment days, with each session lasting less than 20 minutes. Clinical trials show that it delivers results comparable to the standard Deep TMS protocol, maintaining high rates of symptom improvement, response and remission.

“Unlike clinics that must acquire new BrainsWay equipment, Serenity patients can take advantage of the accelerated protocol right now,” said Pease. “This milestone will help improve nationwide accessibility for those struggling with depression and anxiety.”

TMS treatment at Serenity has an 84% response rate and a 78% remission rate, with results lasting over three years for most patients. The FDA’s recent clearance of the accelerated Deep TMS protocol underscores the growing recognition of this therapy’s effectiveness.

To book an appointment, visit www.serenitymentalhealthcenters.com or call 844-310-1649.

About Serenity Mental Health Centers

Serenity Mental Health Centers is a leading provider of comprehensive mental health services, dedicated to transforming the lives of patients through compassionate, innovative, and evidence-based care. With 35 locations across the country, Serenity offers a wide range of treatments tailored to address various mental health conditions, including depression, anxiety, OCD and PTSD. Our highly skilled team of psychiatrists, nurse practitioners and mental health specialists combine innovative therapies like Transcranial Magnetic Stimulation (TMS) and ketamine infusion with personalized care to help patients achieve lasting wellness. Serenity is committed to expanding access to quality mental health care and fostering hope and recovery for individuals and families in the communities we serve. For more information, go to serenitymentalhealthcenters.com.

Accelerated TMS protocol at Serenity delivers results comparable to the standard TMS approach, with 84% response and 78% remission rates.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+1.37 (0.56%)
AAPL  268.47
-1.30 (-0.48%)
AMD  233.54
-4.16 (-1.75%)
BAC  53.20
-0.09 (-0.17%)
GOOG  279.70
-5.64 (-1.98%)
META  621.71
+2.77 (0.45%)
MSFT  496.82
-0.28 (-0.06%)
NVDA  188.15
+0.07 (0.04%)
ORCL  239.26
-4.54 (-1.86%)
TSLA  429.52
-16.39 (-3.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.